{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:22:41Z","timestamp":1761488561248,"version":"build-2065373602"},"reference-count":71,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.transci.2010.09.006","type":"journal-article","created":{"date-parts":[[2010,10,8]],"date-time":"2010-10-08T05:08:39Z","timestamp":1286514519000},"page":"393-399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The status of pathogen-reduced plasma"],"prefix":"10.1016","volume":"43","author":[{"given":"S. Gerald","family":"Sandler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2010.09.006_b0005","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1309\/RAPQ3NXG3MV9AL94","article-title":"Pathogen inactivation\/A new paradigm for preventing transfusion-transmitted infections","volume":"128","author":"McCullough","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.transci.2010.09.006_b0010","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.tmrv.2004.11.005","article-title":"Protecting the blood supply from emerging pathogens: the role of pathogen inactivation","volume":"19","author":"Allain","year":"2005","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.transci.2010.09.006_b0015","doi-asserted-by":"crossref","first-page":"719","DOI":"10.5858\/2007-131-719-PITDSF","article-title":"Pathogen inactivation: the definitive safeguard for the blood supply","volume":"131","author":"Bryant","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.transci.2010.09.006_b0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.transci.2008.05.003","article-title":"Pathogen reduction of blood components","volume":"39","author":"Solheim","year":"2008","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2010.09.006_b0025","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.tmrv.2008.12.004","article-title":"Properties of pathogen-inactivated plasma components","volume":"23","author":"Prowse","year":"2009","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.transci.2010.09.006_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tmrv.2007.09.001","article-title":"Proceedings of a consensus conference: pathogen inactivation\u2013making decisions about new technologies","volume":"22","author":"Webert","year":"2008","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.transci.2010.09.006_b0035","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.transci.2006.10.002","article-title":"Pathogen-reduction systems for blood components: the current position and future trends","volume":"35","author":"Seghatchian","year":"2006","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2010.09.006_b0040","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.tracli.2009.04.004","article-title":"Protecting the blood supply from emerging pathogens: the role of pathogen inactivation","volume":"16","author":"Blajchman","year":"2009","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.transci.2010.09.006_b0045","first-page":"5","article-title":"10years of pathogen reduction\/inactivation (PR\/PI)","volume":"6","author":"Allain","year":"2009","journal-title":"Transfus Today"},{"key":"10.1016\/j.transci.2010.09.006_b0050","first-page":"36","article-title":"Inactivation of hepatitis B and Hutchinson strain of non-A, non-B virus by exposing to Tween 80 and ether","volume":"46","author":"Prince","year":"1984","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2010.09.006_b0055","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1046\/j.1537-2995.1985.25686071422.x","article-title":"Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri-n-(butyl) phosphate detergent combinations","volume":"25","author":"Horowitz","year":"1985","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2010.09.006_b0060","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1046\/j.1537-2995.1998.38198141508.x","article-title":"Current status of solvent\/detergent-treated frozen plasma","volume":"38","author":"Klein","year":"1998","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.transci.2010.09.006_b0065","first-page":"1","article-title":"ARC and VITEX finalize distribution agreement for solvent\/detergent-treated plasma","volume":"4","author":"Anonymous","year":"1998","journal-title":"AABB Wkly Rep"},{"key":"10.1016\/j.transci.2010.09.006_b0070","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/MOH.0b013e3282e9a433","article-title":"It is time to bring back solvent\u2013detergent plasma","volume":"14","author":"Sandler","year":"2007","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.transci.2010.09.006_b0075","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/01.moh.0000137915.88478.23","article-title":"Solvent\/detergent-treated plasma: composition, efficacy and safety","volume":"11","author":"Hellstern","year":"2004","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.transci.2010.09.006_b0080","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.transci.2008.05.005","article-title":"Fresh-frozen plasma, pathogen-reduced single-donor plasma or bio-pharmaceutical plasma?","volume":"39","author":"Hellstern","year":"2008","journal-title":"Transfus Apher Sci"},{"issue":"2","key":"10.1016\/j.transci.2010.09.006_b0085","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1423-0410.2007.00940.x","article-title":"Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura","volume":"93","author":"Scully","year":"2007","journal-title":"Vox Sang"},{"issue":"3","key":"10.1016\/j.transci.2010.09.006_b0090","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1053\/j.jvca.2006.09.002","article-title":"Fatal fibrinolysis during orthotopic liver transplantation in patients receiving solvent\/detergent-treated plasma (Octaplas)","volume":"21","author":"Magner","year":"2007","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"4","key":"10.1016\/j.transci.2010.09.006_b0095","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00001721-199308000-00011","article-title":"Evaluation of solvent\/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders","volume":"4","author":"Inbal","year":"1993","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.transci.2010.09.006_b0100","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1473-0502(02)00104-0","article-title":"The Norwegian plasma fractionation project \u2013 a 12 year clinical and economic success story","volume":"28","author":"Flesland","year":"2003","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2010.09.006_b0105","unstructured":"Krusius T. Optimizing the use of plasma in Finland moving to Octaplas. In: Symposium: plasma safety: meet the expert, Cairo, Egypt, March 23, 2009."},{"issue":"12","key":"10.1016\/j.transci.2010.09.006_b0110","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1182\/blood-2008-04-152520","article-title":"Prion diseases are efficiently transmitted by blood transfusion in sheep","volume":"112","author":"Houston","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.transci.2010.09.006_b0115","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(04)15486-X","article-title":"Possible transmission of variant Creutzfeldt\u2013Joacob disease by blood transfusion","volume":"363","author":"Llewelyn","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2010.09.006_b0120","unstructured":"Knight R. Prions, prion disease and blood. In: Symposium: plasma safety: meet the expert, Cairo, Egypt, March 23, 2009."},{"issue":"3","key":"10.1016\/j.transci.2010.09.006_b0125","first-page":"134","article-title":"Virus-inactivated plasma \u2013 PlasmaSafe: a one-year experience","volume":"5","author":"De Silvestro","year":"2007","journal-title":"Blood Tranfus"},{"key":"10.1016\/j.transci.2010.09.006_b0130","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood.V74.1.517.517","article-title":"Use of 8-methoxypsoralen and long wavelength ultraviolet radiation for decontamination of platelet concentrates","volume":"74","author":"Lin","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.transci.2010.09.006_b0135","series-title":"Blood banking and transfusion medicine","first-page":"3383","article-title":"Virus-safe products: pathogen reduction and inactivation","author":"Corash","year":"2007"},{"key":"10.1016\/j.transci.2010.09.006_b0140","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/j.1537-2995.2005.00216.x","article-title":"Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies","volume":"45","author":"de Alarcon","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2010.09.006_b0145","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1046\/j.1537-2995.2002.00220.x","article-title":"Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin","volume":"42","author":"Hambleton","year":"2002","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2010.09.006_b0150","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1423-0410.2003.00351.x","article-title":"Preclinical profile of plasma prepared using the Intercept blood system","volume":"85","author":"Ciaravino","year":"2003","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2010.09.006_b0155","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/j.1537-2995.2006.00867.x","article-title":"Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function","volume":"46","author":"Singh","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2010.09.006_b0160","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1182\/blood-2004-03-0930","article-title":"Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease","volume":"107","author":"Mintz","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.transci.2010.09.006_b0165","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1537-2995.2007.01594.x","article-title":"Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers","volume":"48","author":"Schlenke","year":"2008","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2010.09.006_b0170","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/j.1537-2995.2009.02579.x","article-title":"An active hemovigilance program characterizing the safety profiler of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment","volume":"50","author":"Cazenave","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2010.09.006_b0175","unstructured":"Kientz D, Cinqualbre J, Hanau D, Isola H, Mendel I, Waller C, et al. Intercept plasma and liver transplantation. In: Fifth international intercept meeting, April 28\u201330, Rome, Italy."},{"key":"10.1016\/j.transci.2010.09.006_b0180","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1537-2995.2004.03355.x","article-title":"Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light","volume":"44","author":"Ruane","year":"2004","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2010.09.006_b0185","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1537-2995.2007.01094.x","article-title":"Inactivation of Orientia tsutsugamushi in red blood cells, plasma and platelets with riboflavin and light, as demonstrated in an animal model","volume":"47","author":"Rentas","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2010.09.006_b0190","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1423-0410.2005.00736.x","article-title":"Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light","volume":"90","author":"Cardo","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2010.09.006_b0195","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.transci.2007.07.002","article-title":"Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavina and ultravioleta Light","volume":"37","author":"Cardo","year":"2007","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2010.09.006_b0200","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1537-2995.2009.02538.x","article-title":"Evaluation of the Mirasol pathogen reduction technology system against Babesia microti in apheresis platelets and plasma","volume":"50","author":"Tonnetti","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2010.09.006_b0205","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.transci.2009.09.006","article-title":"The influence of riboflavin photochemistry on plasma coagulation factors","volume":"41","author":"Larrea","year":"2009","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2010.09.006_b0210","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1537-2995.2009.02517.x","article-title":"Mirasol pathogen-reduced FFP Smith J, Rock G. Protein quality in Mirasol pathogen reduction technology-treated apheresis-derived fresh-frozen plasma","volume":"50","author":"Buytaet-Hoefen","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2010.09.006_b0215","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1111\/j.1537-2995.2009.02272.x","article-title":"Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulation proteins","volume":"49","author":"Hornsey","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2010.09.006_b0220","unstructured":"Mirasol PRT-treated fresh frozen plasma meets the Council of Europe Guidelines for untreated protein quality. (Council of Europe, European Directorate for the Quality of Medicine and Healthcare of the Council of Europe. Guide to the Preparation, Use & Quality Assurance of Blood Components. 14th ed. Strasbourg, 2008. ISBN 978-92-871-6330-1)."},{"key":"10.1016\/j.transci.2010.09.006_b0225","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1537-2995.2009.02517.x","article-title":"Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma","volume":"50","author":"Smith","year":"2010","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.transci.2010.09.006_b0230","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1423-0410.2009.01238.x","article-title":"Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at \u221230[degrees]C\/Blood component-collection and production","volume":"98","author":"Bihm","year":"2010","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2010.09.006_b0235","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/ajcn\/63.1.54","article-title":"Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans","volume":"63","author":"Zempleni","year":"1996","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.transci.2010.09.006_b0240","first-page":"75","article-title":"Studies on the toxicity and pharmacology of riboflavin","volume":"76","author":"Unna","year":"1942","journal-title":"J Pharmacol"},{"key":"10.1016\/j.transci.2010.09.006_b0245","first-page":"15","article-title":"Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level","volume":"80","author":"Kumar","year":"2004","journal-title":"Photochem Photobiol"},{"key":"10.1016\/j.transci.2010.09.006_b0250","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.transci.2006.01.007","article-title":"The Mirasol PRT. System for pathogen reduction of platelets and plasma: an overview of current status and future trends","volume":"35","author":"Goodrich","year":"2006","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2010.09.006_b0255","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3181\/00379727-28-5512","article-title":"Photodynamic action of certain dyes on the inactivation of staphylococcus bacteriophage","volume":"28","author":"Clifton","year":"1931","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.transci.2010.09.006_b0260","first-page":"288","article-title":"The photodynamic action of methylene blue on certain viruses","volume":"112","author":"Perdrau","year":"1933","journal-title":"Proc R Soc Lond (Biol)"},{"key":"10.1016\/j.transci.2010.09.006_b0265","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/tmrv.2002.29405","article-title":"Virus inactivation in blood components by photoactive phenothiazine dyes","volume":"16","author":"Wagner","year":"2002","journal-title":"Transfus Med Rev"},{"issue":"4","key":"10.1016\/j.transci.2010.09.006_b0270","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1423-0410.1991.tb00907.x","article-title":"Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light","volume":"60","author":"Lambrecht","year":"1991","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2010.09.006_b0275","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.transci.2008.04.004","article-title":"Updates on pathogen inactivation of plasma using Theraflex methylene blue system","volume":"38","author":"Seghatchian","year":"2008","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2010.09.006_b0280","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.1537-2995.2004.03424.x","article-title":"West Nile virus in plasma is highly sensitive to methylene blue-light treatment","volume":"44","author":"Mohr","year":"2004","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2010.09.006_b0285","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1011-1344(04)00118-6","article-title":"Inactivation of dengue virus by methylene blue\/narrow bandwidth system","volume":"77","author":"Huang","year":"2004","journal-title":"J Photochem Photobiol B (Biol)"},{"key":"10.1016\/j.transci.2010.09.006_b0290","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1423-0410.2006.00840.x","article-title":"The efficacy of photochemically treatment with methylene blue and light for the reduction of Trypanosoma cruzi in infected plasma","volume":"91","author":"Girones","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2010.09.006_b0295","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.transci.2005.02.002","article-title":"The influence of methylene blue light treatment and methylene blue filter on fibrinogen activity states and fibrin polimerisation indices","volume":"33","author":"Depasse","year":"2005","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2010.09.006_b0300","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1046\/j.1537-2995.2003.00483.x","article-title":"Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety?","volume":"43","author":"Williamson","year":"2003","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2010.09.006_b0305","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1537-2995.2008.02039.x","article-title":"Thrombin generation and clot formation in methylene blue treated plasma and cryoprecipitate","volume":"49","author":"Cardigan","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2010.09.006_b0310","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000202413","article-title":"Thrombin generation capacity of methylene blue-treated plasma prepared by the Theraflex MB plasma system","volume":"36","author":"Gravemann","year":"2009","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.transci.2010.09.006_b0315","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1537-2995.2009.02484.x","article-title":"Quality of methylene blue-treated fresh-frozen plasma stored up to 27months 9letter","volume":"50","author":"Moog","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2010.09.006_b0320","unstructured":"FDA Liasion Meeting \u2013 10\/29\/08. Accessed on May 22, 2010 at www.aabb.org>Meetings & Events>Government\/Advisory Meetings>FDA Liasion Meetings>Blood and Blood Components."},{"key":"10.1016\/j.transci.2010.09.006_b0325","unstructured":"FDA Liasion Meeting 1\/7\/2010. Accessed on May 22, 2010 at www.aabb.org>Meetings & Events>Government\/Advisory Meetings>FDA Liasion Meetings>Blood and Blood Components."},{"key":"10.1016\/j.transci.2010.09.006_b0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tmrv.2007.09.001","article-title":"Proceedings of a consensus conference. pathogen inactivation \u2013 making decisions about new technologies","volume":"22","author":"Webert","year":"2008","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.transci.2010.09.006_b0335","first-page":"125","article-title":"Current status of pathogen inactivation methods","volume":"5","author":"AuBuchon","year":"2010","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2010.09.006_b0340","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1046\/j.1423-0410.2003.00329.x","article-title":"Cost-effectiveness of solvent\/detergent-treated fresh-frozen plasma","volume":"85","author":"Riedler","year":"2003","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2010.09.006_b0345","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/jca.20198","article-title":"TRALI risk reduction: donor and component management strategies","volume":"24","author":"Eder","year":"2009","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2010.09.006_b0350","unstructured":"Eder AF, Herron Jr RM, Strupp A, Dy B, White J, Notari EP, et al. Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006\u20132008). Transfusion, in press."},{"key":"10.1016\/j.transci.2010.09.006_b0355","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.moh.0000177832.70657.33","article-title":"The case for pathogen inactivation of blood components","volume":"12","author":"Sandler","year":"2005","journal-title":"Curr Opin Hematol"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050210001503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050210001503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:48:42Z","timestamp":1761468522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050210001503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S1473050210001503"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2010.09.006","relation":{},"ISSN":["1473-0502"],"issn-type":[{"type":"print","value":"1473-0502"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The status of pathogen-reduced plasma","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2010.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}